Osteopontin is a tumor autoantigen in prostate cancer patients

Tilli,Tatiana  M.; Silva,Eloísio  A.; Matos,Lívia  C.; Faget,Douglas V.; Dias,Bianca  F.P.; Vasconcelos,Juliana  S.P.; Yokosaki,Yasuyuki; Gimba,Etel R.P.

doi:10.3892/ol.2010.211

Osteopontin is a tumor autoantigen in prostate cancer patients

Authors:
- Tatiana M. Tilli
- Eloísio A. Silva
- Lívia C. Matos
- Douglas V. Faget
- Bianca F.P. Dias
- Juliana S.P. Vasconcelos
- Yasuyuki Yokosaki
- Etel R.P. Gimba
View Affiliations

Affiliations: Programa de Medicina Experimental and Biologia Celular and Post Graduation Program in Oncology, Coordenação de Pesquisa, Instituto Nacional de Câncer, Universidade do Estado do Rio de Janeiro, Rio de Janeiro-RJ, Brazil, Serviço de Urologia, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro-RJ, Brazil, Universidade de Brasília, Brasília-DF, Brazil, Cell-Matrix Frontier Laboratory Biomedical Research Building, Hiroshima University, Minamiku, Hiroshima, Japan
Published online on: November 23, 2010 https://doi.org/10.3892/ol.2010.211
Pages: 109-114

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anti-tumor antibodies act as biomarkers for the early diagnosis of prostate cancer (PCa). Osteopontin (OPN) is overexpressed in PCa cells and contributes to the progression of the disease. This study aimed to evaluate whether OPN evokes a humoral immune response in PCa patients and whether the reactivity levels of anti-OPN antibodies may be used to better differentiate PCa from benign and healthy donor plasma samples. Plasma samples from biopsy-proven PCa patients (29), benign prostate hyperplasia (BPH) (18) and control healthy donors (HD) (30) were tested by immunoblots using the recombinant human OPN. The frequency of anti-OPN antibodies was significantly higher in PCa (66%) plasma samples as compared to BPH (33%) and HD controls (10%). Anti-OPN antibodies were detected in a high proportion of plasma samples from patients with a Gleason score of less than 6 (57%), prostate-specific antigen levels lower than 10 ng/ml (67%) and pT2 organ-confined disease (70%), suggesting that anti-OPN antibodies may be used as an early serum marker for PCa. To the best of our knowledge, this is the first description of OPN as a tumor autoantigen and one of the most reactive individual autoantigens described thus far. These data support the inclusion of OPN in a multiplex of tumor antigens in order to perform antibody profiling in PCa as well as in other malignancies overexpressing OPN.

View Figures

View References

1	Miller J and Tarter TH: Update on the use of dutasteride in the management of benign prostatic hypertrophy. Clin Interv Aging. 2:99–104. 2007. View Article : Google Scholar : PubMed/NCBI
2	Taylor BS, Pal M, Yu J, et al: Humoral response profiling reveals pathways to prostate cancer progression. Mol Cell Proteomics. 7:600–611. 2008. View Article : Google Scholar : PubMed/NCBI
3	Lu H, Goodell V and Disis ML: Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res. 7:1388–1394. 2008. View Article : Google Scholar : PubMed/NCBI
4	Cho-Chung YS: Autoantibody biomarkers in the detection of cancer. Biochim Biophys Acta. 1762:587–591. 2006. View Article : Google Scholar : PubMed/NCBI
5	Lubin R, Schlichtholz B, Teillaud JL, et al: p53 antibodies in patients with various types of cancer: assay, identification and characterization. Clin Cancer Res. 1:1463–1469. 1995.PubMed/NCBI
6	Storr SJ, Chakrabarti J, Barnes A, et al: Use of autoantibodies in breast cancer screening and diagnosis. Expert Rev Anticancer Ther. 6:1215–1223. 2006. View Article : Google Scholar : PubMed/NCBI
7	Bachelot T, Ratel D, Menetrier-Caux C, et al: Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer. 94:1066–1070. 2006. View Article : Google Scholar : PubMed/NCBI
8	Vural B, Chen LC, Saip P, et al: Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer. 103:2575–2583. 2005. View Article : Google Scholar : PubMed/NCBI
9	Jacobs JP, Pettit AR, Shinohara ML, et al: Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody-mediated arthritis. Arthritis Rheum. 50:2685–2694. 2004. View Article : Google Scholar : PubMed/NCBI
10	Stromnes IM and Goverman JM: Osteopontin-induced survival of T cells. Nat Immunol. 8:19–20. 2007. View Article : Google Scholar : PubMed/NCBI
11	Shevde LA, Das S, Clark DW, et al: Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 10:71–81. 2010. View Article : Google Scholar : PubMed/NCBI
12	Fedarko NS, Jain A, Karadag A, et al: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 7:4060–4066. 2001.PubMed/NCBI
13	Hotte SJ, Winquist EW, Stitt L, et al: Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer. 95:506–512. 2002. View Article : Google Scholar : PubMed/NCBI
14	Wai PY and Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 27:103–118. 2008. View Article : Google Scholar : PubMed/NCBI
15	Forootan SS, Foster CS, Aachi VR, et al: Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer. 118:2255–2261. 2006. View Article : Google Scholar : PubMed/NCBI
16	Sakata M, Tsuruha JI, Masuko-Hongo K, et al: Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol. 28:1492–1495. 2001.PubMed/NCBI
17	Yokosaki Y, Matsuura N, Sasaki T, et al: The integrin alpha(9) beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem. 274:36328–36334. 1999. View Article : Google Scholar
18	Chung CT, Niemela SL and Miller RH: One-step preparation of competent Escherichia coli: trasformation and storage of bacterial cells in the same solution. Proc Natl Acad Sci USA. 86:2172–2175. 1989.PubMed/NCBI
19	Sardana G, Dowell B and Diamandis EP: Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem. 54:1951–1960. 2008. View Article : Google Scholar : PubMed/NCBI
20	Bensalah K, Lotan Y, Karam JA, et al: New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis. 11:112–120. 2008. View Article : Google Scholar : PubMed/NCBI
21	Du H, Masuko-Hongo K, Nakamura H, et al: The prevalence of autoantibodies against cartilage intermediate layer protein, YKL-39, osteopontin, and cyclic citrullinated peptide in patients with early-stage knee osteoarthritis: evidence of a variety of autoimmune processes. Rheumatol Int. 26:35–41. 2005. View Article : Google Scholar
22	Watanabe M, Uchida K, Nakagaki K, et al: Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 581:2017–2021. 2007. View Article : Google Scholar : PubMed/NCBI
23	Tomer Y, Sherer Y and Shoenfeld Y: Autoantibodies, autoimmunity and cancer. Oncol Rep. 5:753–761. 1998.PubMed/NCBI
24	Adler AJ: Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones. Curr Cancer Drug Targets. 7:3–14. 2007. View Article : Google Scholar : PubMed/NCBI
25	Casiano CA, Mediavilla-Varela M and Tan EM: Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics. 5:1745–1759. 2006. View Article : Google Scholar : PubMed/NCBI
26	Thalmann GN, Sikes RA, Devoll RE, et al: Osteopontin: possible role in prostate cancer progression. Cancer Res. 5:2271–2277. 1999.PubMed/NCBI
27	Bradley SV, Oravecz-Wilson KI, Bougeard G, et al: Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res. 65:4126–4133. 2005. View Article : Google Scholar : PubMed/NCBI
28	Pontes ER, Matos LC, da Silva EA, et al: Auto-antibodies in prostate cancer: humoral immune response to antigenic determinants coded by the differentially expressed transcripts FLJ23438 and VAMP3. Prostate. 66:1463–1473. 2006. View Article : Google Scholar : PubMed/NCBI
29	Shi F, Zhang J, Liu D, et al: Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate. 63:252–258. 2005. View Article : Google Scholar : PubMed/NCBI
30	Sreekumar A, Laxman B, Rhodes DR, et al: Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst. 96:834–843. 2004. View Article : Google Scholar : PubMed/NCBI
31	Leman ES and Getzenberg RH: Biomarkers for prostate cancer. J Cell Biochem. 108:3–9. 2009. View Article : Google Scholar : PubMed/NCBI